Oramed Pharmaceuticals Net Income

Oramed Pharmaceuticals (ORMP) currently reports a net income of $190M as of June 2026. That compares with $-24M in the prior-year period — up 870.4% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Oramed Pharmaceuticals's net income history and peer comparisons.

Oramed Pharmaceuticals's net income increased from $-24M to $190M — a 870.4% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Oramed Pharmaceuticals's net income of $190M is lower than the Healthcare sector average of $16B. That is roughly 98.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Oramed Pharmaceuticals reported $190M in net income as of June 2026. That compares with $-24M in the prior-year period — up 870.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $190M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Oramed Pharmaceuticals, and consider following ORMP for alerts when major investors trade the stock.